Company will highlight May 25 NDA approval in marketing of its levothyroxine product. King projects second quarter sales of over $20 mil., up from $17.3 mil. in the first quarter. Levoxyl is the second approved levothyroxine product after Watson/Jerome Stevens's Unithroid. Abbott plans to file an NDA for its market leader Synthroid before FDA's Aug. 14 deadline (1"The Pink Sheet" May 7, p. 21)
You may also be interested in...
Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials